Relapsed and refractory hematologic malignancies have a very poor prognosis. Chimeric antigen receptor T cells are emerging as a powerful therapy in this setting. Early clinical trials of genetically modified T cells for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia have shown high complete response rates in patients with few therapeutic options. Exploration is ongoing for other hematologic malignancies including multiple myeloma, acute myeloid leukemia, and Hodgkin lymphoma (HL). At the same time, the design and production of chimeric antigen receptor T cells are being advanced so that this therapy can be more widely utilized. Cytokine release syndrome and neurotoxicity are common, but they are treatable and fully reversible. This review will review available data as well as future developments and challenges in the field.
G enetic modification of T cells to express chimeric antigen receptors (CARs) offers a novel approach to treating hematologic malignancies. Like monoclonal antibodies, CAR T cells are targeted therapies directed against a cell-surface antigen on malignant cells. Chimeric antigen receptor T cells are potentially more potent than monoclonal antibodies and can establish longlived immunity against the target antigen after a single infusion. As a result, compared with monoclonal antibodies, the criteria for target selection are more stringent because of severe toxicity that can develop if the target is expressed on noncancerous cells. 1, 2 Over the past decade, immunotherapy with CAR T cells has evolved from bench to bedside with promising early clinical results. In early-phase clinical trials at several centers, CAR T cells have induced impressive responses in chemotherapy-refractory chronic lymphocytic leukemia (CLL) and relapsed acute lymphoblastic leukemia (ALL). There are now a variety of CAR target antigens under investigation for multiple hematologic malignancies (Table 1 ). In this review, we will discuss CAR T-cell design, production, and clinical use. We review the early-phase clinical data on CAR T cells for non-Hodgkin lymphoma (NHL), CLL, and ALL and touch upon the emerging use of CAR T cells in other hematologic malignancies. In addition, we discuss the toxicities encountered and their management strategies.
CHIMERIC ANTIGEN RECEPTOR DESIGN
Chimeric antigen receptors are engineered receptors that artificially confer specificity of T lymphocytes for native cell-surface antigens. 3 Chimeric antigen receptors consist of an extracellular antigen-binding domain, a hinge region, a transmembrane domain, and an intracellular signaling domain (Fig. 1) . The antigenbinding domain typically comprises a single-chain variable fragment (scFv), derived from a monoclonal antibody. Unlike the native T-cell receptor, CARs recognize their targets independently of antigen processing by the target cell and independently of the major histocompatibility complex. [4] [5] [6] Binding of the antigen to the extracellular domain leads to T-cell activation via the intracellular signaling domains. Early CAR designs contained the CD3ζ chain as the only intracellular signaling domain and are referred to as first-generation CARs. Preclinical and clinical studies have shown that the addition of costimulatory signaling domains to the intracellular component improves T-cell proliferation and persistence. 7, 8 Secondgeneration CARs incorporate a single costimulatory domain (e.g., CD28 or 4-1BB), whereas third-generation CARs incorporate 2 costimulatory domains (e.g., both CD28 and 4-1BB). The optimum choice and configuration of costimulatory signaling domains are uncertain and under investigation.
PRODUCTION AND CLINICAL USE OF CAR T CELLS
Manufacturing of CAR T cells requires collection of autologous T cells via leukopheresis followed by ex vivo genetic modification to express the CAR on the T-cell surface and expansion to generate a clinically effective cell dose ( Fig. 2) . Several approaches to gene transfer and ex vivo expansion have been developed.
Gene Transfer Techniques
The first gene transfer system used for CAR T cells used a γ retroviral vector. γ Retroviruses integrate into genomic DNA leading to permanent and heritable CAR expression. Chimeric antigen receptors manufactured in this fashion are safe, are relatively easy to produce, and can efficiently and permanently transduce T cells. Human immunodeficiency virus-based lentiviral vectors are also able to efficiently and permanently transduce T cells. Lentiviral vectors enable higher and more stable CAR expression compared with γ retroviruses. 9 They have a theoretical safety advantage; because of their preferred sites of integration into the genome, they are considered less genotoxic than γ retroviral vectors. 10 However, they are more costly to produce.
Potential disadvantages to viral vectors include cost, expertise required for production, and regulatory requirements. Transposon systems and electroporation of mRNA constructs have both been used as alternatives to viral vectors. Transposons (such as Sleeping Beauty), such as retroviral vectors, can stably integrate into the genome, but they may require long duration of T-cell culture to produce adequate cell doses. [11] [12] [13] Electroporation of mRNA constructs is inexpensive and less technically complex. It is considered safer than viral alternatives because there is no genome integration. However, mRNA is unstable, resulting in CAR expression that is only transient and not heritable. This may be useful in circumstances where only transient CAR activity is desirable, such as when the target antigen is also found in normal tissues. Although there is no potential for establishment of longterm immunity, the antitumor effect could be prolonged via serial CAR T-cell infusions. In preclinical models, anti-CD19 CARs produced by mRNA electroporation showed comparable efficacy to those produced by lentiviral transduction, although clinical results, as discussed below, suggest that long-lived in vivo CAR T-cell persistence, which is not possible with mRNA transfection, is associated with superior outcomes. [14] [15] [16] 
T-Cell Expansion Ex Vivo
After introduction of the vector into the T cells, the cells must then be expanded ex vivo. The T cells are most often stimulated using anti-CD3/anti-CD28 monoclonal antibody-coated magnetic beads. Additional exogenous cytokines (such as interleukin [17] [18] [19] [20] The optimal time for ex vivo expansion is unknown, and studies have used a culture period ranging from 1 to 6 weeks. Most groups achieve several hundredto several thousand-fold T-cell expansion within this short period. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Adoptive Transfer
Both murine models and clinical trials have shown that in vivo proliferation and persistence of adoptively transferred T cells are augmented when patients receive some form of lymphodepleting therapy, either radiation or chemotherapy, a few days prior to T-cell infusion. 24, [29] [30] [31] Lymphodepletion prior to infusion of CAR T cells is thought to create homeostatic space for T-cell expansion and deplete other cells that would compete for available cytokines. 32, 33 The optimal T-cell dose and number of infusions are unknown, and the level of T-cell engraftment and expansion does not always correlate with the dose of T cells given. Once CAR T cells are infused back into the host, they rapidly redistribute throughout the body. [34] [35] [36] Chimeric antigen receptor T cells then undergo accumulation at the sites of target recognition. It is unclear how long CAR T cells must persist within the host to continue immunosurveillance and prevent relapse.
CHIMERIC ANTIGEN RECEPTOR T CELLS IN HEMATOLOGIC MALIGNANCIES
An ideal target for CAR T cells is an antigen detected on tumor cells but not on normal tissues, therefore limiting the "on target, off tumor" toxicity. In this regard, both CD19 and CD20 are good CAR targets for most B-cell malignancies, including B-cell ALL, CLL, and B-cell NHL, as the only expected antigen-specific toxicity is B-cell aplasia and subsequent hypoglobulinemia, which is manageable with immunoglobulin replacement therapy. Peripheral blood mononuclear cells (PBMCs) are collected from the patient via apheresis, and stimulated peripheral blood mononuclear cells are exposed to the viral or nonviral vector. T cells are stimulated using anti-CD3/anti-CD28 monoclonal antibody-coated magnetic beads with or without additional exogenous cytokines. Patients then receive lymphodepleting chemotherapy followed by infusion of CAR T cells. 
Non-Hodgkin Lymphoma and CLL
The earliest clinical work with CAR T cells in hematologic malignancies was in patients with B-cell NHL. Although initial studies were small, they helped inform further research. At City of Hope, first-generation anti-CD20 and anti-CD19 CAR T cells were tested in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Although the therapy was well tolerated, T-cell persistence was limited. At 1 week after infusion, detectable levels of transferred T cells were found only after 3 of 15 infusions, and poor persistence of CAR T cells was observed. 21 T-cell persistence improved with the addition of a costimulatory domain. The National Cancer Institute (NCI) used a second-generation anti-CD19 CAR with a CD28 costimulatory domain in a patient with advanced FL. The patient received lymphodepleting chemotherapy followed by CAR T-cell infusion and intravenous IL-6 every 8 hours for 8 doses. The patient had a partial response (PR) that lasted 32 weeks. B-cell aplasia was present in the peripheral blood from approximately 9 weeks after T-cell infusion until at least 39 weeks. The anti-CD19 CAR T cells persisted in the peripheral blood until 27 weeks after T-cell infusion. 29 Subsequently, our institution, the University of Pennsylvania (Penn), reported results from treatment of 3 patients with advanced, chemotherapy-resistant CLL using an anti-CD19 CAR with a CD137 (4-1BB) costimulatory domain (CTL019, previously referred to as CART19) administered following lymphodepleting chemotherapy. Notably, CTL019 cells persisted in the blood of all patients for at least 6 months. Of the 3 patients treated, there were 2 patients with complete response (CR) and 1 patient with PR lasting greater than 8 months after CART19 infusion. 26, 37 The importance of lymphodepleting chemotherapy for in vivo persistence of CAR T cells was highlighted in a study at Memorial Sloan Kettering Cancer Center (MSKCC) in which 10 patients with refractory CLL and relapsed ALL were treated with an anti-CD19 CAR T cell with a CD28 costimulatory domain (19-28z). The 7 patients who received 19-28z immediately following lymphodepleting chemotherapy had significantly more durable persistence of 19-28z cells in the peripheral blood and bone marrow compared with the 3 patients who did not receive lymphodepleting chemotherapy. 24 Over the last year, results have been reported from multiple centers evaluating second-generation anti-CD19 CAR T cells in B-cell NHL and CLL. Kochenderfer et al. 38 at the NCI treated 15 patients with NHL with an anti-CD19 CAR with a CD28 costimulatory domain. Of the 7 evaluable patients with DLBCL, 4 obtained CR, 2 obtained PR, and 1 had stable disease after infusion of CAR T cells. This was the first report of antitumor efficacy of an anti-CD19 CAR T cell in aggressive lymphoma. At Penn, Schuster et al. 39 recently reported interim results from 19 NHL patients treated with CTL019. The overall response rate for the entire cohort was 68%; by histology, 6 of 13 DLBCL patients, 7 of 7 FL patients, and 1 of 2 mantle cell lymphoma patients exhibited at least PRs. It is too early to make conclusions about the long-term durability of the responses observed in NHL. A recently published update of the initial CTL019 study in CLL is encouraging regarding response durability, however, as the 2 initially reported CRs are ongoing more than 4 years after treatment, and 2 additional subjects from this cohort of 14 also attained durable minimal residual disease (MRD)-negative CRs. 40 There are many ongoing trials of anti-CD19 CAR T cells in patients with lymphoma. Alternative clinical settings are being evaluated including the administration of CAR T cells after autologous stem cell transplantation (ASCT) (NCT01840566) and as a bridge to allogeneic transplant (NCT02431988). 41, 42 Thirdgeneration constructs are being studied (NCT02132624). Targets other than CD19 are also being investigated including CD30 (NCT02259556, NCT01316146, NCT02274584) and CD22 (NCT02315612).
Acute Lymphoblastic Leukemia
Perhaps the most exciting results from the early experience with CAR T-cell therapy have been in B-cell ALL. The prognosis of ALL in the relapsed or refractory setting is dismal, with remission rates with standard chemotherapy of approximately 30%. 43 The MSKCC group was the first to show antitumor efficacy in a small group of patients with ALL. Five patients with relapsed ALL underwent lymphodepleting chemotherapy and were treated with 19-28z, and eligible patients then underwent allogeneic stem cell transplantation. All 5 patients achieved MRD-negative status after T-cell infusion, enabling them to undergo transplantation if they were otherwise eligible. 44 Investigators at Penn and the Children's Hospital of Philadelphia published a report of 30 adults and children with relapsed or refractory ALL who received CTL019. Complete response was achieved in 27 of the 30 patients at 6 months. Patients had persistence of CAR T cells and B-cell aplasia for up to 2 years. Remissions of 2 to 24 months were seen in 19 of the 27 responding patients. Event-free survival and overall survival at 6 months were 67% and 78%, respectively. 45, 46 Similarly encouraging results have been reported at other centers. Davila et al. 47 at MSKCC treated 16 patients with 19-28z and had a CR rate of 88%. The 19-28z cells persisted for 1 to 3 months, and 7 patients were able to proceed to allogeneic stem cell transplant. All of these patients were in CR at the time of publication. Lee et al. 48 at the NCI reported 21 children and young adults who received a second-generation anti-CD19 CAR T cells with a CD28 costimulatory domain. The CR rate was 70%, and the longest persistence of CAR T cell was 68 days. Overall survival at a median follow-up of 10 months was 51.6%, and leukemia-free survival in the 12 patients who achieved MRD-negative CR was 78.8%. Ongoing studies are evaluating larger patient cohorts.
ADDITIONAL TARGETS IN HEMATOLOGIC MALIGNANCIES

Acute Myeloid Leukemia
A challenge of adapting CAR T-cell therapy for use in myeloid malignancies is the identification of a target that is present on tumor cells but absent from normal myeloid cells and their precursors. Two acute myeloid leukemia (AML) targets have been identified that would be expected to spare normal myelopoiesis: the Lewis Y (LeY) antigen and NKG2D. The LeY antigen is an oligosaccharide that is structurally related to the Lewis blood group antigens but not expressed on erythrocytes and has limited expression on other normal tissues. This antigen is, however, expressed in high number in many malignancies including AML. 49 A phase I study of 4 patients with high-risk AML using a second-generation anti-LeY CAR T cell with a CD28 costimulatory domain showed that the therapy was well tolerated and effective. Three of the 4 patients had responses, but all eventually had progressive disease despite persistence of CAR T cells. 35 NKG2D is an activating cell surface receptor expressed on natural killer (NK) cells and a variety of other immune cells; its ligand is overexpressed by many tumor cells. Preclinical models have demonstrated the antitumor efficacy of a NKG2D CAR construct in a variety of settings. [50] [51] [52] [53] [54] [55] However, the expression on multiple different immune cells can lead to severe off-target toxicity in preclinical models. 56 An ongoing clinical trial is evaluating the safety of a CAR T cell directed against NKG2D ligands in patients with AML, myelodysplastic syndrome, and multiple myeloma (MM) (NCT02203825).
Preclinical studies have investigated CD33 or CD123 as targets. While both are expressed on AML blasts and normal hematopoietic stem/progenitor cells, CD123 is expressed to a much lesser degree on normal tissues. Preclinical models have shown that both antigens are effective targets for CAR T cells in reduction of tumor burden, but as expected, there is less killing of normal progenitor cells by anti-CD123 CAR T cells. 57, 58 An ongoing trial in China (NCT01864902) reported results of 1 patient treated with anti-CD33 CAR T-cell therapy with a 4-1BB costimulatory domain. Although the patient had a marked decrease in blast percentage at 2 weeks, this was followed by a gradual increase and disease progression. This occurred despite the persistence of CAR T cells at high levels in the bone marrow and peripheral blood for at least 2 months. In addition, the patient experienced toxicities including cytokine release syndrome (CRS) and pancytopenia. 59 A study of an anti-CD123 CAR T cell at City of Hope
is not yet open for recruitment (NCT02159495). Myelotoxicity of CARs against these targets might be manageable if they use transient expression systems such as mRNA transfection and are used as a bridge to allogeneic stem cell transplantation. 57, 58 
Multiple Myeloma
Multiple targets have been investigated in preclinical and clinical settings for CAR T cells in MM. 60 Chimeric antigen receptors targeting CS1, CD38, CD138, B-cell maturation antigen (BCMA), CD44v6, LeY, κ light chain, and NKG2D have demonstrated preclinical anti-MM activity. The clinical studies mentioned previously testing LeY-and NKG2D-targeted CARs in myeloid malignancies are also enrolling patients with MM. Additional clinical studies of CARs targeting CS1, BCMA, CD138, and κ light chain are ongoing but have not yet published results.
B-cell maturation antigen and CS1 are the targets with the most substantiated rationale in MM. These antigens are expressed on MM plasma cells in nearly all patients with little expression on nonmalignant cells. B-cell maturation antigen expression is restricted to late-stage B cells and plasma cells. 61 CS1 is expressed on plasma cells and, at low levels, on NK cells and subsets of T cells and activated monocytes and dendritic cells. 62 Chimeric antigen receptors against both BCMA and CS1 have antimyeloma activity in vitro and in murine models. 63 We have recently reported a case in which CTL019 administered after ASCT led to durable complete response despite this patient's very poor response to prior ASCT. 65 Although CD19 is not expressed on the dominant population of MM plasma cells in most patients, it can be found on minor subsets of the MM clone, and several lines of evidence suggest that these CD19 + subsets might be uniquely drug-resistant and clonogenic. 66 Further study is required to determine which patients might benefit from this approach and to better understand the mechanism of action of CTL019 in this predominantly CD19-negative neoplasm.
Hodgkin Lymphoma
An attractive target in Hodgkin lymphoma (HL) is CD30, which is expressed on Hodgkin Reed-Sternberg (HRS) cells. However, CD30 is also present on some activated T cells, and so CAR T cells with this target could theoretically induce fratricide, limiting the utility of the therapy. There are preclinical data demonstrating that CD30-directed CAR T cells can target CD30 + Hodgkin cell lines, and there are a number of ongoing clinical trials evaluating this target (NCT02259556, NCT01316146, NCT02274584). 67, 68 However, the HRS cells make up only a small portion of the tumor, which is characterized largely by the immunosuppressive microenvironment. Therefore, the ideal target would be expressed on both populations of cells. A group at our institution identified CD123 as a potential target because it is expressed on both HRS cells and immune cells of the microenvironment, and they have presented preclinical data showing the efficacy of a CD123 CAR T-cell construct against disseminated HL. 69 
TOXICITY OF CAR T CELLS B-Cell Aplasia
Toxicities from CAR T cells can result from the effects of the target antigen on nontumor cells, the so-called "on target, off tumor" effect, or truly off-target effects in which the CAR crossreacts to an unintended target antigen. B-cell aplasia is seen in patients treated with CD19 CAR T cells. 23, 29, 38, 45, 46 The duration of B-cell aplasia is variable, depending on the construct and costimulatory molecules used. It is associated with hypogammaglobulinemia that responds to intravenous immunoglobulin replacement therapy. Other targets would be expected to have different "on target, off tumor" effects, and these are described in more details above. Fortunately, off-target toxicity of CARs for hematologic malignances has not been identified, but our group recently reported off-target fatal cardiotoxicity of autologous T cells redirected toward the cancer-testis antigen MAGE-A3 using a lentivirally transduced affinity-enhanced T-cell receptor. 70, 71 
Cytokine Release Syndrome
In some patients, CAR T cells induce an inflammatory reaction called CRS. Clinical manifestations can range from isolated fever to hemodynamic collapse with multisystem organ failure. This syndrome can resemble macrophage activation syndrome with hepatosplenomegaly, hyperferritinemia, and hypofibrinogemia. 45, 46 Cytokine release syndrome generally develops within 1 to 2 weeks of CAR T-cell infusion. 23, 38, 44, 46 The onset of clinical symptoms correlates with the peak in vivo expansion of CAR T cells and the levels of inflammatory cytokines, particularly interferon γ, IL-10, and IL-6. 37, 38, [44] [45] [46] 48 Patients with greater disease burden at the time of CAR T-cell infusion tend to have a more severe syndrome. 44, 46 Occurrence of CRS may not be a prerequisite to achieve antitumor control. 44 Although in mild cases the syndrome resolves uneventfully without intervention, patients with severe CRS often require intensive supportive care including the administration of vasopressors and respiratory support. 47 Reversal of severe CRS requires the use of either corticosteroids or the IL-6 receptor-blocking antibody, tocilizumab. While corticosteroids can in some cases quickly reverse symptoms, they can also decrease the expansion of CAR T cells. Suppression of CAR T cells presumably has a negative effect on tumor control. For example, in 1 study, all 3 patients who were treated with steroids experienced disease recurrence despite achieving CR after initial CAR T-cell therapy. Conversely, tocilizumab can improve clinical symptoms and is not thought to impair expansion or function of T cells. 47 Thus, tocilizumab is typically the first choice for management of CRS that requires intervention, except in severe cases where combination of tocilizumab and corticosteroids might be considered.
Neurotoxicity
Patients who receive CAR T cells can develop reversible neurotoxicity independently of CRS. While global encephalopathy is the most common toxicity, other symptoms have been reported (seizures, aphasia, hallucinations). Most commonly, the symptoms are brief and self-limited. They resolve over several days without intervention, and patients do not appear to have any long-term sequelae. In fact, the administration of tocilizumab or corticosteroids does not appear to alter outcome. 38, 46 Imaging (computed tomography or magnetic resonance imaging) and lumbar puncture have not identified an etiology for these symptoms. 38, [46] [47] [48] Neurotoxicity does not appear to be associated with the presence of CAR T cells in the cerebrospinal fluid. 47 Similar toxicity has been described with the anti-CD19 biospecific T-cell engager blinatumomab. 72 This toxicity needs to be further characterized going forward.
CONCLUSIONS
The optimal CAR T-cell design and application continue to be actively explored for many hematologic malignancies. In small studies at several centers, CD19 seems to be a safe and effective target for CAR T cells in early-phase clinical trials in ALL, CLL, NHL, and more recently MM. There are several promising targets for CAR therapy in MM, notably BCMA and CS1 that are currently in phase I clinical trials. Identification of safe targets for myeloid neoplasms is more challenging, but transient or reversible CAR expression techniques may enable use of CARs against myeloid antigens such as CD123 or CD33, particularly in patients with available donors for allogeneic transplantation.
Target identification is only 1 consideration in clinical development for CAR T cells. As indicated by the very different response rates with anti-CD19 CARs between CLL and ALL, disease-specific factors may affect CAR function. Choices regarding CAR design and manufacturing processes also affect efficacy and toxicity profiles and may need to be tailored to host-and disease-specific immune parameters. Similarly, the optimal position of CAR T-cell therapy in relation to existing therapies will need to be determined. Determining, for each disease, the optimal targets, CAR designs, and points of integration with existing therapies will require continued innovation and collaboration between laboratory-based and clinical investigators.
